KOL Views: How problematic are new safety concerns about Novartis’ Beovu?

Multiple reports emerged over the past few days raising questions about the risk/benefit profile of Beovu (brolucizumab), a drug recently approved for wet age-related macular degeneration (AMD) that Novartis is in the early stages of introducing into a market dominated by Eylea (aflibercept) from Regeneron Pharmaceuticals and Bayer.

To provide FirstWord readers with rapid feedback on how much impact the newly emergent adverse events will have on prescribing patterns for anti-VEGF drugs, we are hosting an expert call with a key opinion leader (KOL) early next week.

Key topics that will be discussed during the call include, among other things… how had you been prescribing Beovu and Eylea prior to the recent news; based on Phase III data, how did Beovu’s risk/benefit profile look relative to Eylea’s; how much does the new safety data change this; what could Novartis do to mitigate concerns about Beovu’s safety profile; what are the biggest question marks about Beovu’s profile; to what extent will the new information change prescribing patterns; and will this have a meaningful impact on the adoption of biosimilar versions of Eylea?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the competition for market share involving Eylea, Beovu and other anti-VEGF drugs.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.